دورية أكاديمية
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
| العنوان: | Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial |
|---|---|
| المؤلفون: | Mina, Roberto, Musto, Pellegrino, Rota-Scalabrini, Delia, Paris, Laura, Gamberi, Barbara, Palmas, Angelo, Aquino, Sara, de Fabritiis, Paolo, Giuliani, Nicola, De Rosa, Luca, Gozzetti, Alessandro, Cellini, Claudia, Bertamini, Luca, Capra, Andrea, Oddolo, Daniela, Vincelli, Iolanda Donatella, Ronconi, Sonia, Pavone, Vincenzo, Pescosta, Norbert, Cea, Michele, Fioritoni, Francesca, Ballanti, Stelvio, Grasso, Mariella, Zamagni, Elena, Belotti, Angelo, Boccadoro, Mario, Gay, Francesca |
| المساهمون: | Mina, R, Musto, P, Rota-Scalabrini, D, Paris, L, Gamberi, B, Palmas, A, Aquino, S, de Fabritiis, P, Giuliani, N, De Rosa, L, Gozzetti, A, Cellini, C, Bertamini, L, Capra, A, Oddolo, D, Vincelli, Id, Ronconi, S, Pavone, V, Pescosta, N, Cea, M, Fioritoni, F, Ballanti, S, Grasso, M, Zamagni, E, Belotti, A, Boccadoro, M, Gay, F |
| بيانات النشر: | ELSEVIER SCIENCE INC |
| سنة النشر: | 2023 |
| المجموعة: | Universitá degli Studi di Roma "Tor Vergata": ART - Archivio Istituzionale della Ricerca |
| مصطلحات موضوعية: | Settore MED/15 - MALATTIE DEL SANGUE |
| الوصف: | Background Patients with newly diagnosed multiple myeloma and high-risk cytogenetic abnormalities (HRCA) represent an unmet medical need. In the FORTE trial, lenalidomide and dexamethasone plus carfilzomib (KRd) induction resulted in a higher proportion of patients with at least a very good partial response as compared with carfilzomib, cyclophosphamide, and dexamethasone (KCd), and carfilzomib plus lenalidomide maintenance prolonged progression-free survival compared with lenalidomide maintenance. In this prespecified analysis of the FORTE trial, we described the outcomes of enrolled patients according to their cytogenetic risk.Methods The UNITO-MM-01/FORTE was a randomised, open-label, phase 2 trial done at 42 Italian academic and community practice centres, which enrolled transplant-eligible patients with newly diagnosed multiple myeloma aged 18-65 years. Eligible patients had newly diagnosed multiple myeloma based on standard International Myeloma Working Group criteria, a Karnofsky performance status of at least 60%, and had not received any previous treatment with anti-myeloma therapy. At enrolment, patients were stratified according to International Staging System stage (I vs II/III) and age (<60 years vs 60-65 years) and randomly assigned (1:1:1) to KRd plus autologous stem-cell transplantation (ASCT; four 28-day induction cycles with KRd, melphalan at 200 mg/m2 and ASCT [MEL200-ASCT], followed by four 28-day KRd consolidation cycles), 12 28-day KRd cycles, or KCd plus ASCT (four 28-day induction cycles with KCd, MEL200-ASCT, and four 28-day KCd consolidation cycles), using a web-based system (block randomisation, block size of 12). Carfilzomib was administered at 20 mg/m2 on days 1 and 2 of cycle 1, followed by 36 mg/m2 intravenously administered on days 8, 9, 15, and 16 of cycle 1, and then 36 mg/m2 intravenously administered for all subsequent doses on days 1, 2, 8, 9, 15, 16; lenalidomide 25 mg was administered orally on days 1-21; cyclophosphamide 300 mg/m2 was administered orally on days 1, 8, ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36528035; info:eu-repo/semantics/altIdentifier/wos/WOS:000921526700001; volume:24; issue:1; firstpage:64; lastpage:76; numberofpages:13; journal:THE LANCET ONCOLOGY; https://hdl.handle.net/2108/318977Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85145336859 |
| DOI: | 10.1016/S1470-2045(22)00693-3 |
| الإتاحة: | https://doi.org/10.1016/S1470-2045Test(22)00693-3 https://hdl.handle.net/2108/318977Test |
| رقم الانضمام: | edsbas.598B0AAE |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/S1470-2045(22)00693-3 |
|---|